Prevention of cisplatin–DNA adduct repair and potentiation of cisplatin-induced apoptosis in ovarian carcinoma cells by proteasome inhibitors
- 25 September 2000
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 60 (9) , 1343-1354
- https://doi.org/10.1016/s0006-2952(00)00455-x
Abstract
No abstract availableKeywords
This publication has 52 references indexed in Scilit:
- DNA damage recognition during nucleotide excision repair in mammalian cellsBiochimie, 1999
- Identification and Characterization of XPC-Binding Domain of hHR23BMolecular and Cellular Biology, 1997
- Disruption of mouse ERCC1 results in a novel repair syndrome with growth failure, nuclear abnormalities and senescenceCurrent Biology, 1997
- DNA EXCISION REPAIRAnnual Review of Biochemistry, 1996
- Cross-resistance to cis-diamminedichloroplatinum(II) of a multidrug-resistant lymphoma cell line associated with decreased drug accumulation and enhanced DNA repairEuropean Journal of Pharmacology, 1996
- Cloning, Comparative Mapping, and RNA Expression of the Mouse Homologues of theSaccharomyces cerevisiaeNucleotide Excision Repair GeneRAD23Genomics, 1996
- Mammalian DNA nucleotide excision repair reconstituted with purified protein componentsCell, 1995
- Mechanisms of DNA Excision RepairScience, 1994
- Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation.Journal of Clinical Investigation, 1991
- Genomic characterization of the human DNA excision repair geneERCC-1Nucleic Acids Research, 1987